Alvotech Holdings SA, develops and manufactures biosimilars for global markets. The company is headquartered in Iceland.
| Revenue (TTM) | $562.04M |
| Gross Profit (TTM) | $345.85M |
| EBITDA | $104.24M |
| Operating Margin | 9.13% |
| Return on Equity | 0.00% |
| Return on Assets | 3.84% |
| Revenue/Share (TTM) | $1.92 |
| Book Value | $-0.91 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | 2.32 |
| EV/Revenue | 4.818 |
| EV/EBITDA | 11.93 |
| Quarterly Earnings Growth (YoY) | -99.00% |
| Quarterly Revenue Growth (YoY) | -20.20% |
| Shares Outstanding | $312.15M |
| Float | $113.59M |
| % Insiders | 62.73% |
| % Institutions | 6.45% |
Volatility is currently expanding